Wegovy is a brand-name injectable semaglutide approved by the FDA in 2021 for chronic weight management in adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related condition. In March 2024, the FDA added a cardiovascular risk-reduction indication for adults with established cardiovascular disease who are overweight or obese. That second indication is what unlocks Medicare Part D coverage, since Medicare was previously prohibited from covering weight-loss-only drugs.
The landscape for Wegovy pricing shifted significantly in mid-2025 and continues to evolve in 2026. Novo Nordisk launched NovoCare Pharmacy in March 2025, providing all Wegovy doses at $499 per month for cash-paying patients. On February 24, 2026, Novo Nordisk announced a list price reduction to $675 per month effective January 1, 2027. The Medicare GLP-1 Bridge, a CMS demonstration program, adds a separate $50 per month pathway for Medicare Part D enrollees beginning July 1, 2026, through December 31, 2027. Patients with diabetes who use semaglutide should also review Ozempic cost — the same molecule approved for diabetes at a different dose.
No generic semaglutide is available at retail pharmacies. Novo Nordisk's patent exclusivity for Wegovy runs until approximately 2031. Compounded semaglutide from 503B outsourcing facilities was available during the shortage period but FDA removed it from the shortage list in late 2024, restricting most compounding. As of 2026, the NovoCare Pharmacy $499 per month option and manufacturer savings programs represent the lowest-cost legitimate access channels for semaglutide. For tirzepatide-based alternatives, see the Zepbound cost guide and Mounjaro cost. Coverage also depends heavily on whether Medicare covers GLP-1 for weight loss.
What Wegovy Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same wegovy can cost many times more at a hospital than at your local pharmacy:
2026 Wegovy Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Retail cash (no insurance) | $1,349/month (list price) | WAC 2026. NovoCare Pharmacy cash price is $499/month. |
| Medicare Part D (GLP-1 Bridge) | $50/month | Flat copay July 1, 2026 to Dec 31, 2027. Does not count toward $2,100 OOP cap. |
| Medicare Part D (CVD indication, standard) | Tier-based, up to $2,100/year OOP cap | For established CVD + overweight or obese. Plan formulary tier determines cost. |
| Commercially insured (with NovoCare Savings Card) | As low as $25/month | Non-government insurance required. No income limit. Cannot be combined with Medicare or Medicaid. |
| Medicaid | $1 to $10/month (where covered) | Coverage varies by state. About 38 states cover GLP-1s for obesity as of 2026. Prior auth required. |
Medicare GLP-1 Bridge $50 copay does not count toward the $2,100 Part D OOP cap in 2026. List price reduction to $675/month takes effect January 1, 2027.
Source: CMS Medicare GLP-1 Bridge (2026), Novo Nordisk WAC, NovoCare Pharmacy pricing
Why Hospitals Charge So Much
Wegovy is a self-administered outpatient drug. Patients inject it at home once weekly. Because it is not infused or administered in a clinical setting, it does not appear on most inpatient hospital bills as a line-item drug charge. The exception is if a patient is admitted for a condition and a physician continues the medication during the stay. In that case, the hospital may bill it at its own acquisition cost plus a facility markup, which can range from 2x to 4x the retail price.
When Wegovy does appear on a hospital bill, it will often be coded under the miscellaneous drug code J3490 (Drug, Not Otherwise Classified) rather than a specific J-code, because CMS has not assigned a dedicated HCPCS code for this formulation. Patients should request an itemized bill and compare any Wegovy charge to the current NovoCare Pharmacy price of $499 per month as a reference point. A hospital charging $1,400 or more per monthly supply for an inpatient stay warrants a review and potential dispute.
The most common hospital billing issue with Wegovy is continuation-of-therapy charges where the patient brought their own pen but the hospital billed it anyway, or where the hospital substituted a higher-priced formulation without notifying the patient. If Wegovy appears on your inpatient bill and you were self-administering it at home before admission, you can dispute that charge as a potential double-billing. Use the CoveredUSA Medical Bill Analyzer to identify and dispute these line items.
Patient Assistance Programs
Novo Nordisk offers multiple savings programs for Wegovy. The right program depends on your insurance status. None of these programs are available to Medicare or Medicaid enrollees.
Patient assistance programs for Wegovy| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NovoCare Savings Card (commercially insured) | As low as $25/month for commercially insured patients. No income limit. | novocare.com/patient/medicines/wegovy/savings-offer.html |
| NovoCare Pharmacy (cash-pay) | $499/month for all dose strengths. Home delivery. No insurance required. | novocare.com/patient/medicines/wegovy.html |
| Novo Nordisk Patient Assistance Program | Free Wegovy for uninsured or underinsured patients with income at or below 400% FPL. | novocare.com/diabetes/help-with-costs/pap.html |
NovoCare Savings Card and NovoCare Pharmacy are not available to Medicare or Medicaid beneficiaries. Medicare GLP-1 Bridge ($50/month) is the primary savings pathway for Medicare enrollees starting July 1, 2026.
Source: NovoCare.com, NeedyMeds.org
Medicare Part D
Medicare Part D has two pathways for covering Wegovy in 2026. The first is the standard Part D formulary pathway: Medicare Part D plans may cover Wegovy when prescribed to reduce cardiovascular risk in adults with established cardiovascular disease who are also overweight or obese. This is the FDA indication added in March 2024. Plans are not required to cover Wegovy for weight loss alone. If your plan covers it, your cost is based on your plan's formulary tier and counts toward the $2,100 annual Part D out-of-pocket cap.
The second pathway is the Medicare GLP-1 Bridge, a CMS demonstration program running July 1, 2026 through December 31, 2027. This program provides Wegovy (injection and tablets) for a flat $50 per month copay to eligible Medicare Part D enrollees. Eligibility requires a BMI of 27 or above with at least one qualifying condition such as heart disease or prediabetes. The $50 copay does not count toward your $2,100 Part D annual OOP cap and does not count toward your Part D deductible. Low-Income Subsidy (LIS) subsidies do not apply to this $50 copay.
Medicare beneficiaries cannot use the NovoCare Savings Card or NovoCare Pharmacy $499 cash program as a supplement to Medicare. Federal law prohibits manufacturers from providing cost-sharing assistance to Medicare beneficiaries. The GLP-1 Bridge $50 pathway and standard formulary coverage are the legitimate Medicare access routes for Wegovy in 2026.
Common Wegovy Billing Errors
If Wegovy appears on your hospital bill or you are being charged more than expected through your pharmacy, check for these billing errors:
- Wegovy billed by hospital when patient brought their own pen from home (double-billing)
- NovoCare Savings Card not applied at pharmacy counter due to processor error (patient overpays hundreds of dollars above $25 cap)
- Medicare Part D plan denying coverage for the cardiovascular indication without requesting prior authorization review
- Billing at the $1,349 WAC list price when patient qualifies for NovoCare Pharmacy $499 program
- GLP-1 Bridge $50 copay incorrectly applied toward Part D deductible or OOP cap (it should not count toward either)
- Hospital billing J3490 (unclassified drug) for Wegovy without attaching required drug identification narrative, causing claim denial and rebilling to patient
Frequently Asked Questions
What is Wegovy's actual cost in 2026?
Wegovy has a list price (WAC) of $1,349 per month in 2026. Most patients pay less. Medicare enrollees can access it for $50 per month through the GLP-1 Bridge program starting July 1, 2026. Commercially insured patients pay as little as $25 per month with the NovoCare Savings Card. Uninsured patients can use NovoCare Pharmacy at $499 per month. The list price drops to $675 per month on January 1, 2027.
Does Medicare cover Wegovy in 2026?
Yes, in two ways. First, standard Medicare Part D plans may cover Wegovy when prescribed for cardiovascular risk reduction in adults with established CVD who are overweight or obese. Second, the Medicare GLP-1 Bridge (starting July 1, 2026) provides Wegovy for a flat $50 per month to eligible Part D enrollees with a BMI of 27 or above and qualifying conditions. The $50 GLP-1 Bridge copay does not count toward your $2,100 annual Part D out-of-pocket cap.
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge is a CMS demonstration program running from July 1, 2026 through December 31, 2027. It provides Wegovy (injection and tablet formulations) at a flat $50 per month copay to eligible Medicare Part D enrollees. Eligibility requires a BMI of 27 or above with at least one qualifying condition (heart disease, prediabetes, or other obesity-related comorbidity). The $50 copay does not count toward the Part D deductible or $2,100 annual OOP cap. Low-Income Subsidy subsidies do not apply to this $50 copay.
How do I get Wegovy for $25 per month?
The NovoCare Savings Card from Novo Nordisk brings the monthly copay to as low as $25 for commercially insured patients. You must have private (non-government) insurance that covers Wegovy. There is no income limit. You cannot use this card if you have Medicare or Medicaid. Enroll at novocare.com and activate at your pharmacy. The savings card is available for 12 months and can be renewed.
Is there a generic version of Wegovy available?
No. As of 2026, there is no FDA-approved generic semaglutide available at retail pharmacies. Novo Nordisk's patent exclusivity for Wegovy runs until approximately 2031. Compounded semaglutide was available from some pharmacies during shortage periods but the FDA removed semaglutide from its shortage list in late 2024, restricting most compounding. The lowest-cost legitimate option for uninsured patients is NovoCare Pharmacy at $499 per month.
Does Medicaid cover Wegovy?
Coverage varies by state. As of 2026, approximately 38 states cover at least one GLP-1 medication for obesity treatment, but coverage, prior authorization criteria, and formulary placement differ significantly by state. Most states require a documented BMI of 30 or above (or 27 with a comorbidity), prior authorization, and documented lifestyle intervention. Some states (including California and Pennsylvania) have restricted or eliminated coverage in 2026. Contact your state Medicaid agency to confirm current coverage.
What is the Wegovy price reduction announced for 2027?
On February 24, 2026, Novo Nordisk announced that Wegovy's list price will drop from $1,349 per month to $675 per month effective January 1, 2027. This represents roughly a 50% list price reduction. A separate Medicare negotiated price of $274 per month under the Inflation Reduction Act's drug negotiation program also takes effect in 2027. The $499 per month NovoCare Pharmacy cash price is available now, before the 2027 list price cut takes effect.
Does Wegovy appear on hospital bills?
Wegovy is self-administered at home once weekly and does not typically appear on inpatient hospital bills. If it does appear, it is usually because a physician continued the medication during an inpatient stay. In that case, the hospital may bill it under the unclassified drug code J3490. If Wegovy appears on your hospital bill but you had your own pen with you, that charge may be a billing error. The CoveredUSA Medical Bill Analyzer can identify and help dispute this type of duplicate charge.
